Biovator and BASF sign technology development agreement

Swedish biotech company Biovator and BASF have signed a collaboration agreement for final development of an in vitro test systems capable of identifying the potential of chemical compounds to induce allergic reaction in humans. The agreement also includes a five-year BASF option of final product deliveries.

Swedish biotech company Biovator and BASF have signed a collaboration agreement for final development of an in vitro test systems capable of identifying the potential of chemical compounds to induce allergic reaction in humans. The agreement also includes a five-year BASF option of final product deliveries.

Based in Stockholm, Biovator is dedicated to the innovation of in vitro test methods for predictive testing of allergic reactions, in both Type 1 and Type 4, to provide alternatives to animal tests. In addition to greatly reducing the need for animal testing, these methods will be faster and less expensive, while providing more reliable results for the chemical, cosmetic, pharmaceutical and food additive industries.

"Allergic reactions to compounds are a serious risk in new products that needs to be discovered in the early stages of product development," says Biovator CEO, Stan Mikulowski. "This collaboration has the potential to open new dimensions in early industrial research that involves testing. The future test product can become an important factor when setting new industry standards."

To meet the significant market and regulatory need for in vitro tests in the pharmaceutical sector, Biovator signed an agreement to co-operate with AstraZeneca R&D in 2007, which was an extension of earlier collaboration.

Companies